Expression of gap junction protein connexin 32 in chronic liver diseases

Liver

Volumn 20, Issue 2, 2000, Pages 104-107

  Yamaoka, Kazuaki ^a   Nouchi, Toshihiko ^b   Kohashi, Takahiro ^a   Marumo, Fumiaki ^c   Sato, Chifumi ^c,d  

^a Hokushin General Hospital   (Japan)

^b Showa General Hospital   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis; Chronic liver disease; Conoexin 32; Gap junction; Immunohistochemical staining; Liver cirrhosis

Indexed keywords

ANTIBODY; CONNEXIN 32; GAP JUNCTION PROTEIN;

ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GAP JUNCTION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; PROTEIN EXPRESSION; VIRUS HEPATITIS;

CHRONIC DISEASE; CONNEXINS; GAP JUNCTIONS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER CIRRHOSIS, ALCOHOLIC;

EID: 0034100310     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2000.020002104.x     Document Type: Article

References (16)

1. KUMAR N, GILULA N. The gap junction communication channel. Cell 1996; 84: 381-8.
2. NICHOLSON B, DERMIETZEL R, TEPLOW D, TRAUB O, WILLECKE K, REVEL J. Two homologous protein components of hepatic gap junctions. Nature 1987; 329: 732-4.
3. YAMAOKA K, NOUCHI T, TAZAWA J, HIRANUMA S, MARUMO F, SATO C. Expression of gap junction protein connexin 32 and E-cadherin in human hepatocellular carcinoma. J Hepatol 1995; 22: 536-9.
4. KNODELL RG, ISHAK KG, BLACK WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 4: 431-5.
5. YAMAOKA K, NOUCHI T, MARUMO F, SATO C. Alpha-smooth-muscle actin expression in normal and fibrotic human livers. Dig Dis Sci 1993; 38: 1473-9.
6. MIYASHITA T, TAKEDA A, IWAI M, SHIMAZU T Single administration of hepatotoxic chemicals transiently decreases the gap-junctional-protein levels of connexin 32 in rat liver. Eur J Biochem 1991; 196: 37-42.
7. HENDRIX E, LOMNETH C, WILFINGER W et al. Quantitative immunoassay of total cellular gap junction protein connexin 32 during liver regeneration using antibodies specific to the COOH-terminus. Tissue Cell 1992; 24: 61-73.
8. FLADMARK K, GJERTSEN B, MOLVEN A, et al. Gap junctions and growth control in liver regeneration and in isolated rat hepatocytes. Hepatology 1997; 25: 847-55.
9. KOJIMA T, YAMAMOTO M, MOCHIZUKI C, et al. Different changes in expression and function of connexin 26 and connexin 32 during DNA synthesis and redifferentiation in primary rat hepatocytes using a DMSO culture system. Hepatology 1997; 26: 585-97.
10. FITZGERALD D, MESNIL M, OYAMADA M, TSUDA H, ITO N, YAMASAKI H. Changes in gap junction protein (Connexin 32) gene expression during rat liver carcinogenesis. J Cell Biochem 1989; 41: 97-102.
11. NEVEU M, HULLY J, PAUL D, PITOT H. Reversible alteration in the expression of the gap junctional protein connexin 32 during tumor promotion in rat liver and its role during cell proliferation. Cancer Commun 1990; 2: 21-31.
12. KRUTOVSKIKH V, OYAMADA M, YAMASAKI H. Sequential changes of gap-junctional intercellular communications during multistage rat liver carcinogenesis. Carcinogenesis 1991; 12: 1701-6.
13. OYAMADA M, KRUTOVSKIKH V, MESNIL M, PARTENSKY C, FRANOISE B, YAMASAKI H. Aberrant expression of gap junction gene in primary human hepatocellular carcinomas: increased expression of cardiac-type gap junction gene connexin 43. Mol Carcinog 1990; 3: 273-8.
14. KRUTOVSKIKH V, MAZZOLENI G, MIRONOV N, et al. Altered homologous and heterologous gap-junctional intercellular communication in primary human liver tumors associated with aberrant protein localization but not gene mutation of connexin 32. Int J Cancer 1994; 56: 87-94.
15. LAIRD D. The life cycle of a connexin: gap junction formation, removal, and degradation. J Bioenerg Biomembr 1996; 28: 311-8.
16. KRUTOVSKIKH V, MESNIL M, MAZZOLENI G, YAMASAKI H. Inhibition of rat liver gap junction intercellular communication by tumor-promoting agents in vivo. Association with aberrant localization of connexin proteins. Lab Invest 1995; 72: 571-7.